Actigraphic assessment of sleep quality in the A4 trial

 描述（由申请方提供）：无症状性阿尔茨海默病（A4）的抗淀粉样蛋白治疗母试验是一项在1000名认知健康、65-85岁的参与者中进行的抗淀粉样蛋白治疗预防认知下降的试验，这些参与者在flobetapir PET扫描中有证据表明其大脑中存在淀粉样蛋白。睡眠质量对生活质量很重要，有证据表明老年人和有患阿尔茨海默病风险的人睡眠质量较差。活动记录仪是一种低成本的非侵入性测量活动的方法，可用于评估睡眠质量，使用像手表一样佩戴的加速度计。我们建议在50名淀粉样蛋白阳性和50名淀粉样蛋白阴性的参与者中增加睡眠质量的活动图评估，这些参与者同意使用A4。我们希望评估抗淀粉样蛋白治疗对睡眠质量的影响，以及基线淀粉样蛋白状态对安慰剂组和淀粉样蛋白阴性组睡眠变化的影响。

 DESCRIPTION (provided by applicant): The Anti-Amyloid Treatment of Asymptomatic Alzheimer's Disease (A4) parent trial is a trial of anti-amyloid therapy for prevention of cognitiv decline in 1000 participants who are cognitively healthy, 65-85 years old, and have evidence of amyloid in their brain on flobetapir PET scans. Quality of sleep is important for quality of life ad there is evidence for poorer sleep quality in older persons and in persons at risk of developing Alzheimer's disease. Actigraphy is a low-cost noninvasive method of measuring activity validated for assessing sleep quality, using an accelerometer that is worn like a wristwatch. We propose to add actigraphic assessment of sleep quality in 50 amyloid-positive and 50 amyloid-negative participants who have consented to A4. We hope to assess the effect of anti-amyloid therapy on sleep quality, and the effect of baseline amyloid status on changes in sleep in the placebo and amyloid-negative group.